Insmed scraps development of sinus drug after mid-stage study failure reut.rs/3L8cgPx
Insmed scraps development of sinus drug after mid-stage study failure
Insmed said on Wednesday it had discontinued the development of its experimental anti-inflammatory drug to treat a chronic sinus condition after it failed to show benefit in a mid-stage study, sending its shares down nearly 17% in extended trading.
reut.rs
December 18, 2025 at 3:01 AM
Insmed scraps development of sinus drug after mid-stage study failure reut.rs/3L8cgPx
Explore the ATS Bronchiectasis Education Center at ATSBEC.com
In collaboration with Insmed.
In collaboration with Insmed.
February 28, 2025 at 1:58 AM
Explore the ATS Bronchiectasis Education Center at ATSBEC.com
In collaboration with Insmed.
In collaboration with Insmed.
Stocks making the biggest moves midday: Palantir, Flutter, United Airlines, Synopsys, Insmed & more
Stocks making the biggest moves midday: Palantir, Flutter, United Airlines, Synopsys, Insmed & more
These are some of the stocks posting the largest moves at midday.
cnb.cx
March 23, 2026 at 5:10 PM
Stocks making the biggest moves midday: Palantir, Flutter, United Airlines, Synopsys, Insmed & more
Check out the new Bronchiectasis Education Center, developed by experts to support pulmonologists, radiologists, and other medical staff who work with these patients. This program was produced in collaboration with Insmed Incorporated. Learn more: atsedplus.thoracic.org/www.atsbec.com
#medsky
#medsky
March 26, 2025 at 1:23 AM
Check out the new Bronchiectasis Education Center, developed by experts to support pulmonologists, radiologists, and other medical staff who work with these patients. This program was produced in collaboration with Insmed Incorporated. Learn more: atsedplus.thoracic.org/www.atsbec.com
#medsky
#medsky
Thanks to everyone joined our social media reception in the #ATS2025 Networking Super Center. We appreciate your likes and shares of important information all year. Thanks to Insmed for supporting the reception.
May 19, 2025 at 3:47 AM
Thanks to everyone joined our social media reception in the #ATS2025 Networking Super Center. We appreciate your likes and shares of important information all year. Thanks to Insmed for supporting the reception.
Και όπως τα λέγαμε να εδώ τι λέει για το θέμα ο CEO της Insmed (mid cap pharma)
May 9, 2026 at 6:46 PM
Και όπως τα λέγαμε να εδώ τι λέει για το θέμα ο CEO της Insmed (mid cap pharma)
If you're attending #ATS2025, check out the Patients & Experts Forum, hosted by the ATS PAR, and RSVP before 5/9.
ATS thanks Genentech, Inc., Insmed Incorporated, and United Therapeutics for their generous support of the ATS 2025 Patients & Experts Forum.
RSVP: forms.monday.com/forms/97f268...
ATS thanks Genentech, Inc., Insmed Incorporated, and United Therapeutics for their generous support of the ATS 2025 Patients & Experts Forum.
RSVP: forms.monday.com/forms/97f268...
April 8, 2025 at 3:15 AM
If you're attending #ATS2025, check out the Patients & Experts Forum, hosted by the ATS PAR, and RSVP before 5/9.
ATS thanks Genentech, Inc., Insmed Incorporated, and United Therapeutics for their generous support of the ATS 2025 Patients & Experts Forum.
RSVP: forms.monday.com/forms/97f268...
ATS thanks Genentech, Inc., Insmed Incorporated, and United Therapeutics for their generous support of the ATS 2025 Patients & Experts Forum.
RSVP: forms.monday.com/forms/97f268...
Bronchiectasis on Good Morning America!!!
Source: Good Morning America share.google/PRaPThVuhcQg...
#Bronchiectasis #BronchiectasisAwareness
Source: Good Morning America share.google/PRaPThVuhcQg...
#Bronchiectasis #BronchiectasisAwareness
Living with bronchiectasis
"GMA" and sponsor Insmed explore life with a rare chronic condition that affects around 500,000 Americans, leaving them unable to do the things they love.
share.google
November 4, 2025 at 8:31 PM
Bronchiectasis on Good Morning America!!!
Source: Good Morning America share.google/PRaPThVuhcQg...
#Bronchiectasis #BronchiectasisAwareness
Source: Good Morning America share.google/PRaPThVuhcQg...
#Bronchiectasis #BronchiectasisAwareness
“So many people starting BRINSUPRI! 👏 Huge credit to Insmed for fast rollout, clear info & a stellar helpline. Bravo‼️
August 29, 2025 at 11:43 PM
“So many people starting BRINSUPRI! 👏 Huge credit to Insmed for fast rollout, clear info & a stellar helpline. Bravo‼️
【ARIKAYCEの正式承認申請、FDAが優先審査】
Insmedのアミカシンリポソーム吸入。MAC肺症に対する一部変更承認申請が優先審査になった。PDUFAは2027年1月28日。加速承認から正式承認へ進める申請であり、いま承認が下りた話ではない。
FDA、Insmedの「ARIKAYCE」正式承認申請を優先審査に指定──MAC肺症へのsNDA、審査完了目標日は2027年1月28日
stellanews.life/technology/1...
Insmedのアミカシンリポソーム吸入。MAC肺症に対する一部変更承認申請が優先審査になった。PDUFAは2027年1月28日。加速承認から正式承認へ進める申請であり、いま承認が下りた話ではない。
FDA、Insmedの「ARIKAYCE」正式承認申請を優先審査に指定──MAC肺症へのsNDA、審査完了目標日は2027年1月28日
stellanews.life/technology/1...
FDA、Insmedの「ARIKAYCE」正式承認申請を優先審査に指定──MAC肺症へのsNDA、審査完了目標日は2027年1月28日
米国食品医薬品局（FDA）は、Insmed社の吸入抗菌薬アミカシンリポソーム吸入用懸濁液（ARIKAYCE）について、MAC（Mycobacterium avium complex）肺症を対象とした正式承認（フル承認）を求める一部変更承認申請（sNDA）を優先審査に指定し、審査完了目標日を2027年1月28日に設定した。
stellanews.life
September 28, 2026 at 4:08 AM
【ARIKAYCEの正式承認申請、FDAが優先審査】
Insmedのアミカシンリポソーム吸入。MAC肺症に対する一部変更承認申請が優先審査になった。PDUFAは2027年1月28日。加速承認から正式承認へ進める申請であり、いま承認が下りた話ではない。
FDA、Insmedの「ARIKAYCE」正式承認申請を優先審査に指定──MAC肺症へのsNDA、審査完了目標日は2027年1月28日
stellanews.life/technology/1...
Insmedのアミカシンリポソーム吸入。MAC肺症に対する一部変更承認申請が優先審査になった。PDUFAは2027年1月28日。加速承認から正式承認へ進める申請であり、いま承認が下りた話ではない。
FDA、Insmedの「ARIKAYCE」正式承認申請を優先審査に指定──MAC肺症へのsNDA、審査完了目標日は2027年1月28日
stellanews.life/technology/1...
Insmed's blood pressure drug meets main goal in mid-stage trial reut.rs/3Tfc5Cm
Insmed's blood pressure drug meets main goal in mid-stage trial
Insmed said on Tuesday that its experimental blood pressure drug met the main and key secondary goals in a mid-stage study, sending shares of the company up 28% in premarket trading.
reut.rs
June 10, 2025 at 11:35 AM
Insmed's blood pressure drug meets main goal in mid-stage trial reut.rs/3Tfc5Cm
Next, ‘Breaking Big in Biotech’ with Neil Kumar (BridgeBio) and William Lewis (Insmed), interviewed by Adam Feuerstein.
NK: we work on genetic diseases, often not interesting for big companies.
WL: it is important to let the street know which direction you are going.
#STATBreakthrough
NK: we work on genetic diseases, often not interesting for big companies.
WL: it is important to let the street know which direction you are going.
#STATBreakthrough
May 19, 2026 at 5:35 PM
Next, ‘Breaking Big in Biotech’ with Neil Kumar (BridgeBio) and William Lewis (Insmed), interviewed by Adam Feuerstein.
NK: we work on genetic diseases, often not interesting for big companies.
WL: it is important to let the street know which direction you are going.
#STATBreakthrough
NK: we work on genetic diseases, often not interesting for big companies.
WL: it is important to let the street know which direction you are going.
#STATBreakthrough
A lovely way to spend an afternoon; with Insmed and some excellent like-minded colleagues in Edinburgh #insmed #bronchiectasis
April 17, 2025 at 6:03 PM
A lovely way to spend an afternoon; with Insmed and some excellent like-minded colleagues in Edinburgh #insmed #bronchiectasis
Insmed (INSM) CEO William Lewis Sells $1.1 Million in Stock
William Lewis, the chair and CEO of Insmed (INSM), sold over $1.1 million worth of the company's stock. This transaction adds to the c…
https://newsstocks.live/news/insmed-insm-ceo-william-lewis-sells-11-million-in-stock #Finance #Markets
William Lewis, the chair and CEO of Insmed (INSM), sold over $1.1 million worth of the company's stock. This transaction adds to the c…
https://newsstocks.live/news/insmed-insm-ceo-william-lewis-sells-11-million-in-stock #Finance #Markets
July 25, 2026 at 4:03 AM
Insmed (INSM) CEO William Lewis Sells $1.1 Million in Stock
William Lewis, the chair and CEO of Insmed (INSM), sold over $1.1 million worth of the company's stock. This transaction adds to the c…
https://newsstocks.live/news/insmed-insm-ceo-william-lewis-sells-11-million-in-stock #Finance #Markets
William Lewis, the chair and CEO of Insmed (INSM), sold over $1.1 million worth of the company's stock. This transaction adds to the c…
https://newsstocks.live/news/insmed-insm-ceo-william-lewis-sells-11-million-in-stock #Finance #Markets
📉 Insider Cluster Sell
6 insiders at INSMED Inc (#$INSM) sold $1.9M in shares over 7 days.
https://earningsfeed.com/companies/1104506-insm-insmed-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_sell
6 insiders at INSMED Inc (#$INSM) sold $1.9M in shares over 7 days.
https://earningsfeed.com/companies/1104506-insm-insmed-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_sell
June 6, 2026 at 2:45 AM
📉 Insider Cluster Sell
6 insiders at INSMED Inc (#$INSM) sold $1.9M in shares over 7 days.
https://earningsfeed.com/companies/1104506-insm-insmed-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_sell
6 insiders at INSMED Inc (#$INSM) sold $1.9M in shares over 7 days.
https://earningsfeed.com/companies/1104506-insm-insmed-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_sell
📰 #Finance
Insmed drops skin disorder candidate after mid-stage trial setback
seekingalpha.com
April 8, 2026 at 11:53 AM
📰 #Finance
The 2025 #RIS2025 has wrapped!
ATS Thanks United Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech USA, GSK, AstraZeneca, Insmed, Lovelace Biomedical, Vicore Pharma, 4D Medical, & Catalent Pharma Solutions for their generous support of the ATS 2025 Respiratory Innovation Summit
ATS Thanks United Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech USA, GSK, AstraZeneca, Insmed, Lovelace Biomedical, Vicore Pharma, 4D Medical, & Catalent Pharma Solutions for their generous support of the ATS 2025 Respiratory Innovation Summit
May 18, 2025 at 4:54 AM
The 2025 #RIS2025 has wrapped!
ATS Thanks United Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech USA, GSK, AstraZeneca, Insmed, Lovelace Biomedical, Vicore Pharma, 4D Medical, & Catalent Pharma Solutions for their generous support of the ATS 2025 Respiratory Innovation Summit
ATS Thanks United Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech USA, GSK, AstraZeneca, Insmed, Lovelace Biomedical, Vicore Pharma, 4D Medical, & Catalent Pharma Solutions for their generous support of the ATS 2025 Respiratory Innovation Summit
The ATS announced a major quality improvement initiative aimed at tackling the persistent and widespread underdiagnosis of bronchiectasis in the U.S. The initiative is made possible through an independent research grant from Insmed Incorporated.
Learn more: site.thoracic.org/press-releas...
Learn more: site.thoracic.org/press-releas...
April 30, 2026 at 7:00 PM
The ATS announced a major quality improvement initiative aimed at tackling the persistent and widespread underdiagnosis of bronchiectasis in the U.S. The initiative is made possible through an independent research grant from Insmed Incorporated.
Learn more: site.thoracic.org/press-releas...
Learn more: site.thoracic.org/press-releas...
📢 Insmed Incorporated is #hiring a Associate Director, Marketing – Disease Education & Integrated Marketing!
🌎 Worldwide
🔗 http://jbs.ink/ilzKgBrRycpo
#jobalert #jobsearch #aviationjobs #remotejob #remotework #wfh #marketing #design
🌎 Worldwide
🔗 http://jbs.ink/ilzKgBrRycpo
#jobalert #jobsearch #aviationjobs #remotejob #remotework #wfh #marketing #design
July 19, 2026 at 2:00 AM
📢 Insmed Incorporated is #hiring a Associate Director, Marketing – Disease Education & Integrated Marketing!
🌎 Worldwide
🔗 http://jbs.ink/ilzKgBrRycpo
#jobalert #jobsearch #aviationjobs #remotejob #remotework #wfh #marketing #design
🌎 Worldwide
🔗 http://jbs.ink/ilzKgBrRycpo
#jobalert #jobsearch #aviationjobs #remotejob #remotework #wfh #marketing #design
Today, join expert Ashley Losier, MD, for an interactive talk, "Ask the Expert: Practical Approaches to #Bronchiectasis Recognition and Care" at 1 p.m. ET on Jan. 28 🗓️This program was produced in collaboration with Insmed Incorporated.
Register now: atsedplus.thoracic.org/content/ask-...
Register now: atsedplus.thoracic.org/content/ask-...
January 28, 2026 at 1:00 PM
Today, join expert Ashley Losier, MD, for an interactive talk, "Ask the Expert: Practical Approaches to #Bronchiectasis Recognition and Care" at 1 p.m. ET on Jan. 28 🗓️This program was produced in collaboration with Insmed Incorporated.
Register now: atsedplus.thoracic.org/content/ask-...
Register now: atsedplus.thoracic.org/content/ask-...
One of my favorite parts of this story is the Insmed CEO who says the "goal of the company is to make medicine available to those patients who can benefit from it," right after the story notes the company isn't launching its new lung disease drug in Europe and the UK citing concerns around MFN.
As the U.S. looks on, European countries feel growing pressure on drug prices
In Europe, two divergent paths are emerging as countries grapple with what to do about drug prices, affecting both pharma and patients — and testing the influence of the U.S.
www.statnews.com
June 10, 2026 at 3:02 PM
One of my favorite parts of this story is the Insmed CEO who says the "goal of the company is to make medicine available to those patients who can benefit from it," right after the story notes the company isn't launching its new lung disease drug in Europe and the UK citing concerns around MFN.